Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest - PubMed (original) (raw)
Clinical Trial
. 2007 May 1;25(13):1670-6.
doi: 10.1200/JCO.2006.09.0928.
Sergio Ricci, Isa Brunetti, Elisabetta Pfanner, Giacomo Allegrini, Cecilia Barbara, Lucio Crinò, Giovanni Benedetti, Walter Evangelista, Laura Fanchini, Enrico Cortesi, Vincenzo Picone, Stefano Vitello, Silvana Chiara, Cristina Granetto, Gianfranco Porcile, Luisa Fioretto, Cinzia Orlandini, Michele Andreuccetti, Gianluca Masi; Gruppo Oncologico Nord Ovest
Affiliations
- PMID: 17470860
- DOI: 10.1200/JCO.2006.09.0928
Clinical Trial
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest
Alfredo Falcone et al. J Clin Oncol. 2007.
Abstract
Purpose: The Gruppo Oncologico Nord Ovest (GONO) conducted a phase III study comparing fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI [irinotecan 165 mg/m2 day 1, oxaliplatin 85 mg/m2 day 1, leucovorin 200 mg/m2 day 1, fluorouracil 3,200 mg/m2 48-hour continuous infusion starting on day 1, every 2 weeks]) with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI).
Methods: Selection criteria included unresectable metastatic colorectal cancer, age 18 to 75 years, and no prior chemotherapy for advanced disease. The primary end point was response rate (RR).
Results: A total of 244 patients were randomly assigned. An increase of grade 2 to 3 peripheral neurotoxicity (0% v 19%; P < .001), and grade 3 to 4 neutropenia (28% v 50%; P < .001) were observed in the FOLFOXIRI arm. The incidence of febrile neutropenia (3% v 5%) and grade 3 to 4 diarrhea (12% v 20%) were not significantly different. Responses, as assessed by investigators, were, for FOLFIRI and FOLFOXIRI, respectively, complete, 6% and 8%; and partial, 35% and 58%, (RR, 41% v 66%; P = .0002). RR confirmed by an external panel was 34% versus 60% (P < .0001). The R0 secondary resection rate of metastases was greater in the FOLFOXIRI arm (6% v 15%; P = .033, among all 244 patients; and 12% v 36%; P = .017 among patients with liver metastases only). Progression-free survival (PFS) and overall survival (OS) were both significantly improved in the FOLFOXIRI arm (median PFS, 6.9 v 9.8 months; hazard ratio [HR], 0.63; P = .0006; median OS, 16.7 v 22.6 months; HR, 0.70; P = .032).
Conclusion: The FOLFOXIRI regimen improves RR, PFS, and OS compared with FOLFIRI, with an increased, but manageable, toxicity in patients with metastatic colorectal cancer with favorable prognostic characteristics. Further studies of FOLFOXIRI in combination with targeted agents and in the neoadjuvant setting are warranted.
Similar articles
- Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.
Masi G, Loupakis F, Salvatore L, Fornaro L, Cremolini C, Cupini S, Ciarlo A, Del Monte F, Cortesi E, Amoroso D, Granetto C, Fontanini G, Sensi E, Lupi C, Andreuccetti M, Falcone A. Masi G, et al. Lancet Oncol. 2010 Sep;11(9):845-52. doi: 10.1016/S1470-2045(10)70175-3. Epub 2010 Aug 9. Lancet Oncol. 2010. PMID: 20702138 Clinical Trial. - Outcome of second-line treatment after first-line chemotherapy with the GONO FOLFOXIRI regimen.
Fornaro L, Vasile E, Masi G, Loupakis F, Baldi GG, Allegrini G, Salvatore L, Cremolini C, Cupini S, Cortesi E, Tuzi A, Granetto C, Brunetti IM, Ricci S, Falcone A. Fornaro L, et al. Clin Colorectal Cancer. 2012 Mar;11(1):71-6. doi: 10.1016/j.clcc.2011.06.013. Epub 2011 Sep 8. Clin Colorectal Cancer. 2012. PMID: 21903485 - Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.
Cremolini C, Antoniotti C, Rossini D, Lonardi S, Loupakis F, Pietrantonio F, Bordonaro R, Latiano TP, Tamburini E, Santini D, Passardi A, Marmorino F, Grande R, Aprile G, Zaniboni A, Murgioni S, Granetto C, Buonadonna A, Moretto R, Corallo S, Cordio S, Antonuzzo L, Tomasello G, Masi G, Ronzoni M, Di Donato S, Carlomagno C, Clavarezza M, Ritorto G, Mambrini A, Roselli M, Cupini S, Mammoliti S, Fenocchio E, Corgna E, Zagonel V, Fontanini G, Ugolini C, Boni L, Falcone A; GONO Foundation Investigators. Cremolini C, et al. Lancet Oncol. 2020 Apr;21(4):497-507. doi: 10.1016/S1470-2045(19)30862-9. Epub 2020 Mar 9. Lancet Oncol. 2020. PMID: 32164906 Clinical Trial. - Chemotherapy of metastatic colorectal cancer.
[No authors listed] [No authors listed] Prescrire Int. 2010 Oct;19(109):219-24. Prescrire Int. 2010. PMID: 21180382 Review. - A systematic review of FOLFOXIRI chemotherapy for the first-line treatment of metastatic colorectal cancer: improved efficacy at the cost of increased toxicity.
Montagnani F, Chiriatti A, Turrisi G, Francini G, Fiorentini G. Montagnani F, et al. Colorectal Dis. 2011 Aug;13(8):846-52. doi: 10.1111/j.1463-1318.2010.02206.x. Epub 2010 Jan 12. Colorectal Dis. 2011. PMID: 20070327 Review.
Cited by
- FOLFOXIRI for First-Line Treatment of Unresectable Colorectal Cancer with Liver Metastases in a Resource-Limited Setting.
Hao VDT, Tri PM, My DT, Anh LT, Trung LV, Bac NH, Vuong NL. Hao VDT, et al. J Gastrointest Cancer. 2024 Oct 31;56(1):12. doi: 10.1007/s12029-024-01133-4. J Gastrointest Cancer. 2024. PMID: 39480530 - NEOADJUVANT TREATMENT OF LIVER METASTASES OF COLORECTAL CANCER: PREDICTIVE FACTORS OF PATHOLOGICAL RESPONSE.
Khessairi N, Mallek I, Mbarek M, Zaafouri EB, Gharbi L, Boufaroua AL, Bacha D, Ben-Slama S. Khessairi N, et al. Arq Bras Cir Dig. 2024 Oct 28;37:e1829. doi: 10.1590/0102-6720202400036e1829. eCollection 2024. Arq Bras Cir Dig. 2024. PMID: 39475884 Free PMC article. - Overall survival with non-proportional hazards in first-line treatment for patients with metastatic colorectal cancer: Systematic review and network meta-analysis.
Keshavarzi F, Salari N, Jambarsang S, Mohammad Tabatabaei S, Shahsavari S, Fournier AJ. Keshavarzi F, et al. Heliyon. 2024 Aug 16;10(16):e36464. doi: 10.1016/j.heliyon.2024.e36464. eCollection 2024 Aug 30. Heliyon. 2024. PMID: 39253267 Free PMC article. - Real-world outcomes of FOLFOXIRI plus bevacizumab in patients with metastatic colorectal cancer: the JSCCR-TRIPON study.
Yamamoto Y, Yukami H, Yamaguchi T, Ohori H, Nagasu S, Kagawa Y, Sugimoto N, Sonoda H, Yamazaki K, Takashima A, Okuyama H, Hasegawa H, Kondo C, Baba E, Matsumoto T, Kawamoto Y, Kataoka M, Shindo Y, Ishikawa T, Esaki T, Kito Y, Sato T, Funakoshi T, Yamaguchi T, Shimada Y, Moriwaki T. Yamamoto Y, et al. Int J Clin Oncol. 2024 Aug 28. doi: 10.1007/s10147-024-02613-0. Online ahead of print. Int J Clin Oncol. 2024. PMID: 39196470 - A multicenter, prospective, non-interventional real-world study to assess the effectiveness of mecapegfilgrastim in preventing neutropenia in patients with gastrointestinal cancer.
Mao C, He Y, Xu N, Yan H, Zhang N, Cheng G, Jiang H, Chen M, Chen Y, Wang X, Gu Y, Shen P, Zhang G, Yan J, Yang Z, Ding L, Han Z, Wang Z, Zhang J, Zheng W, Wang J, Qin S. Mao C, et al. Immun Inflamm Dis. 2024 Aug;12(8):e1348. doi: 10.1002/iid3.1348. Immun Inflamm Dis. 2024. PMID: 39105572 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical